公开(公告)号：US20160272588A1

公开(公告)日：2016-09-22

申请号：US15074027

申请日：2016-03-18

Applicant: Genentech, Inc.

Inventor： Robert Blake ,  Paola Di Lello ,  Jake Drummond ,  Christine Johanna Heideker ,  Lorna Kategaya ,  Till Maurer ,  Jeremy M. Murray ,  Chudi Ndubaku ,  Richard Pastor ,  Lionel Rouge ,  Vickie Tsui ,  Ingrid E. Wertz ,  Kebing Yu

IPC: C07D213/73 ,  A61K45/06 ,  C07D409/04 ,  A61K31/4436 ,  C07D213/74 ,  C07D401/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/496 ,  A61K31/4439 ,  A61K31/44 ,  A61K31/5355

CPC classification number: C07D213/73 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K45/06 ,  C07D213/74 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04

Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

公开(公告)号：US20160108113A1

公开(公告)日：2016-04-21

申请号：US14884542

申请日：2015-10-15

Applicant: Genentech, Inc.

Inventor： Gai Ayalon ,  Till Maurer

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K39/3955 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  G01N2800/28 ,  G01N2800/2828 ,  G01N2800/2835

Abstract: The present invention relates to anti-alpha-synuclein (anti-α-synuclein) antibodies and methods of using the same.

Abstract translation: 本发明涉及抗α-突触核蛋白（抗α-突触核蛋白）抗体及其使用方法。

公开(公告)号：US09732148B2

公开(公告)日：2017-08-15

申请号：US14884542

申请日：2015-10-15

Applicant: Genentech, Inc.

Inventor： Gai Ayalon ,  Till Maurer

IPC: C07K16/18 ,  A61K39/395 ,  C07H21/04

CPC classification number: C07K16/18 ,  A61K39/3955 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/565 ,  G01N2800/28 ,  G01N2800/2828 ,  G01N2800/2835

Abstract: The present invention relates to anti-alpha-synuclein (anti-α-synuclein) antibodies and methods of using the same.

公开(公告)号：US09573899B2

公开(公告)日：2017-02-21

申请号：US15074027

申请日：2016-03-18

Applicant: Genentech, Inc.

Inventor： Robert Blake ,  Paola Di Lello ,  Jason Drummond ,  Christine Johanna Heideker ,  Lorna Kategaya ,  Till Maurer ,  Jeremy M. Murray ,  Chudi Ndubaku ,  Richard Pastor ,  Lionel Rouge ,  Vickie Tsui ,  Ingrid E. Wertz ,  Kebing Yu

IPC: C07D213/02 ,  C07D213/73 ,  A61K31/44 ,  A61K45/06 ,  C07D409/04 ,  A61K31/4436 ,  A61K31/5355 ,  C07D401/04 ,  A61K31/444 ,  A61K31/506 ,  A61K31/496 ,  A61K31/4439 ,  C07D213/74 ,  C07D403/04

CPC classification number: C07D213/73 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5355 ,  A61K45/06 ,  C07D213/74 ,  C07D401/04 ,  C07D403/04 ,  C07D409/04

Abstract: 2-Aminopyridine compounds of Formula I are provided, and various substituents including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for modulating USP7, and for treating cancer and immune disorders such as inflammation mediated by USP7. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract translation: 提供了式I的2-氨基吡啶化合物，以及可用于调节USP7的各种取代基，包括立体异构体，互变异构体和其药学上可接受的盐，以及用于治疗癌症和免疫病症如USP7介导的炎症。 公开了使用式I化合物进行体外，原位和体内诊断以及哺乳动物细胞或相关病理学条件下的这些疾病的治疗的方法。